DalsnaFinance › Analyst accuracy › Canaccord Genuity › BHVN target
Biohaven Pharma stock maintained at buy by Canaccord on licensing deal
Canaccord reiterated a Buy rating and $21.00 price target
A fact about what Canaccord Genuity published, as reported by Investing.com, not a recommendation from Dalsna Finance; Canaccord Genuity is not affiliated with this site.
Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.